The anti-PD-1 antibody camrelizumab (SHR-1210) is being evaluated in combination with apatinib in patients with advanced HCC and gastric cancer (GC) or esophagogastric junction cancer (EGJC). Here, PDCD1 is linked to gastric cancer.